valu usd unless otherwis note
view came away alxn call excit detail
grow pipelin stabl increas confid light
revenu guidanc highli conserv base solid run-rat
strong volum growth histori conserv guidanc
came away alxn call excit detail grow
pipelin stabl increas confid light revenu
guidanc link first blush highli conserv base
factor soliri sale suggest annual
run-rat alreadi approach lower end
product volum growth number soliris/ultomiri treat
patient estim doubl
histori quarterli guidanc rais throughout consecut
guidanc rais throughout follow call buyer
guide-rel weak given confid quarterli beat
rais year come
aggress increas ultomiri switch forecast result
pt reduct though see switch-rel
franchis protect net win stock soliri post solid
investor focu amidst stock weak follow quarter
buyer weak given see guidanc highli conserv
soliri yoy growth indic year ahead
gmg continu grow percentag soliri sale note
soliri yoy price headwind primarili driven
one-tim reimburs headwind launch intern market
turkey follow recent market author yoy price
headwind call management reiter goal convert
current us soliri patient ultomiri within year
soliri pnh patient enrol onesourc program half
patient alreadi treat utlomiri adjust
model toward aggress switch goal model ultomiri
captur complement therapi market share vs
soliri note faster switch rate decreas revenu estim
pnh franchis given price discount infrequ dose
vs biweekli mainten ultomiri vs soliri see note
addit dose-rel discount widen price gap
reinforc pricing-rel switch incent ahu gmg market
conserv model soliri uptak gmg larg drive
revenu growth slightli guidanc
view conserv given histori past upward revis
lower end
higher end ultim report
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
price target base sum-of-the-part
sotp methodolog estim probability-adjust
npv follow soliri sale pnh soliri
sale ahu strensiq sale
share kanuma sale lal-d soliri sale
mg soliri sale nmo
compani project cash posit
compani debt posit
price target support outperform rate
upsid scenario assum faster-than-
expect uptak metabol franchis
regulatori approv pnh clinic success
trial ahu
downsid scenario assum
approv pnh addit neg readout ahu
mg nmosd addit assum discount
soliri npv base earlier-than-anticip biosimilar
entri case expect stock trade base
valu discount soliri busi metabol
despit pnh patient competit like soliri
mg approv see declin soliri pnh sale
larg off-set expans ahu mg focu
long-term revenu expens guidanc amid intens
development competit field complement
inhibitor anticip restructur could help remov
near-term overhang stock follow manag
could help protect pnh ahu
market competitor see dose
regimen promis highli conveni though riski
development strategi present pk
dose use remain unclear
whether recycl strategi use extend half
life hold high concentr note
therapeut antibodi commerci
high dose though conced dose would
like seen conveni mani competitor
ip extens like fend soliri biosimilar
see recent composit matter formul
method use patent extend ip us
hold launch biosimilar anticip issuanc
similar patent eu extend protect
eu countri view biosimilar soliri near-term
upcom potenti catalyst eu approv
pnh approv soliri nmosd
initi phase studi nmosd
risk factor neg influenc valuat
rate includ develop setback includ
pnh posit develop
progress competitor complement program
excit despit tepid pnh ahu growth report upbeat soliri
launch gmg patient therapi repres q/q growth
patient growth rate slow initi q/q growth rate
view highli impress given much larger patient base
grow management note refractori gmg popul current
soliri signific room growth becom largest us soliri indic
model soliris-tr gmg patient gmg growth beyond
gmg approv commerci soliri nmosd sbla file improv
traction amidst neurolog clinician model peak risk-unadjust global sale
po soliris/ultomiri nmosd
recent caelum bioscienc deal repres pragmat busi develop strategi
management commit continu management allot fund busi
develop see deal recent announc deal caelum
bioscienc see note offer higher back-end payout littl up-front payment
earli stage clinic asset rare ultra-rar diseas although phase data
al amyloidosi patient us/eu shown promis mean
improv mean gl score week keep indic upsid
model wait addit detail get construct around program
model updat oper expens came neg
impact ip relat syntimmun asset acquisit
model expens in-lin guidanc
sg expens in-lin guidanc provid model
metabol revenu vs guidanc st
compani report capit market estim
chang model revenu expens expens expens incom incom expens incom incom non- non- exhibit incom statement
compani report capit market estim
compani report capit market estim
soliri pnh ahu lal-d mg nmo pnh ahu mg nmo valu stock dilut share outstand net market sum-of-the-part valuat
compani report capit market estim
price target base sum-of-the-part sotp methodolog
estim probability-adjust npv follow soliri sale pnh soliri
sale ahu strensiq sale kanuma sale lal-d
share soliri sale mg soliri sale nmo
compani project cash posit compani debt
posit price target support outperform rate
risk rate price target
factor neg influenc valuat rate includ develop
set-back includ neg readout studi ahu posit develop
progress competitor complement program
alexion pharmaceut global fulli integr biopharmaceut compani
focus treatment rare diseas lead commerci product soliri eculizumab
human monoclon antibodi direct complement factor soliri approv
treatment paroxysm nocturn hemoglobinuria pnh atyp hemolyt urem
syndrom ahu gener myasthenia gravi three ultra-rar diseas caus
uncontrol complement activ alexion aim expand soliri neurolog
transplant disord conduct late-stag develop program neuromyel optica
nmo delay graft function dgf antibody-medi reject amr
alexion also market strensiq asfotas alfa enzym replac therapi ert indic
hypophosphatasia grant us approv octob eu approv
septemb approv japan juli addit
acquisit synageva alexion own kanuma sebelipas alfa ert treatment
lysosom acid lipas defici lal-d receiv eu us market approv
septemb decemb respect approv japan march
compani current develop next gener complement inhibitor
treatment pnh ahu potenti complement associ diseas
